With the aim of understanding the origin (in terms of market cap) of multibagger stocks of the last decade, we performed an analysis wherein we looked at the returns of all the listed stocks. We did this analysis with a hypothesis that small/micro cap companies, as compared to mid and large cap, would be the home to majority of multibagger socks today. Though the hypothesis turned out to be correct but it amazed us how small rather micro cap companies turned out to be the den for ~98% of all the 50x+ stocks (46 in total) in the last decade.
Before running into the analysis, few points to help a reader:
– There are four market cap categories – A) below 50 crores, B) 50-500 crores, C) 500-1,000 crores and D) above 1,000 crores
– Returns are expressed in the form of ‘number of times’ stock price has become from starting date, 01 June 2005
– There are three time periods across which this analysis has been performed A) 10 year: Jun 2005 – Jun 2015, B) 5 year: Jun 2010 – Jun 2015 and C) 3 year: Jun 2012 to Jun 2015
– Stock prices are split and bonus adjusted
– Market cap in INR cr is as on starting date
– Source: Ace Equity, there could be some misses because of the availability of data on the database

Top gainers – Symphony Ltd, Manappuram Finance, Optiemus Infracom, Caplin Point, Bliss GVS, Urja Global, Dhanuka Agritech, Shilpa Medicare, Mayur Uiquoters, Cera, Ajanta, Pharma, Kitex, Relaxo, EPC Industrie, Ashiana, Poddar Developers, Amara Raja, SCUF, Vinati, La Opa

Top gainers – Cigniti Technologies, Ajanta Pharma, Arrow Coated, Avanti Feeds, Caplin Point, Indo Count, Kellton Tech, La Opala, Stampede Capital, Optiemus Infracom, Kitex

Top gainers – Indo Count, Arrow Coated, Atlas Jewellery, Marksans Pharma, Smiths & Founders, Trinity Tradelink , Cressanda Solutions , Pressman Advertising, Nutraplus India , PI Industries
For the 10 year period there were 261 stocks which became 10+ baggers. Of these, more than 50% belonged to <50 crore market cap, 24% belonged to 50-500 crore and rest 20% to above 500 crore.
Based on this analysis one can not overlook the importance of analyzing smaller companies.
Starting today, we intend to initiate a series of posts, Catch Me If You Can, where our effort will be to understand, of course with the benefit of hindsight, whether there was a way to figure out the improving fundamentals of these (multibagger) companies while they were small. To perform this analysis our major focus would be on management commentary for the last ten years and on the financial statements.
Catch Me If You Can #1 – PI Industries
Products and services
Operating segments – Agrochemicals and custom synthesis and contract manufacturing (CRAMS)
Agrochemicals – PI has a portfolio of herbicides, insecticides, fungicide and specialty plant nutrient products & solutions
CRAMS – For agrochemicals, pharma intermediates and other niche fine chemicals for global innovators
Salient features of this compounding engine
Diversification into new business line (2005) – Entered CRAMS, which is a high margin low capex business. CRAMS also provides cushion, to P&L, against cyclical nature of domestic agrochemicals business
Focus on core business (2011) – Exited polymer compound business, which had a low margin and volatile earning profile
Introduction of new products at regular intervals – Strategic introduction of 4-5 new products every year leading to top-line growth irrespective of how monsoons had been
Business model
- CRAMS – Agreements with innovators at early stage of molecules provided an opportunity to PI to benefit from the entire life-cycle of the final product there by leading to predictable revenue stream for long term
- Agrochemicals – Marketing and distribution tie-ups with foreign innovators in agrochemicals to manufacture and/or sell their product in India putting PI on high growth trajectory
Distribution network – Well penetrated network of 9k distributors and 40k retailers
How were numbers behaving – was there any clue?
FY09 proved to be the inflection point in the history of PI, a look at below table shows how improvement started taking place in FY09. In this year, company’s gross margins improved by ~200 bps, EBITDA margins by ~400 bps, for the first time in last 3 years revenue grew by ~24%, debt levels declined and all of this resulted in improved ROCE and ROE of 18% and 30% respectively. PI recorded such returns ratios for the first time in the last decade.

If we go back and take a look at the annual reports for the year 2008 and 2009, there are quite a lot indicators which point towards improving business profile of the company, in terms of both – growth as well as margins. For e.g. in 2008, management talks about depressed earnings during the year because of high investments in fast growing highly profitable CRAMS business indicating margins improvement from here on.
Posting some clippings of management commentary from annual report for the year FY08 and FY09.
Snippets from FY08 annual report

Snippets from FY09 annual report

Stock price performance

During whole of FY09, PI was available in the P/E range 5-10x TTM earnings. It continued to trade in the P/E band of 3-13x TTM earnings till FY12. Table below shows average TTM P/E of PI for the years – FY08 till FY13. This was a long window of opportunity to buy this business at an attractive valuation without taking any undue risks on business quality.

As mentioned above this whole analysis has the huge benefit of hindsight. But what we are trying to do through this look-back is to find clues which could perhaps have helped us if one was in the past. Using these clues we can perhaps learn a few mental hacks that can be given much more importance when we read the annual report of a new company which mentions similar things.
Comments invited!
Disclaimer: This is not a recommendation to Buy/Sell/Hold. Registration Status with SEBI: I am not registered with SEBI under SEBI (Research Analysts) Regulations, 2014. As per the clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”